Antimicrobial spectrum and features
The group demonstrates expanded capabilities compared to its predecessors:
- Gram-positive flora: increased efficacy against pneumococci, streptococci, staphylococci, including methicillin-resistant strains (MRSA).
- Gram-negative flora: high level of activity is fully preserved.
- Atypical flora: intracellular pathogens are inhibited as effectively as by macrolides and tetracyclines (Chlamydia spp., Legionella spp., Mycoplasma spp.).
- Anaerobes: as exemplified by moxifloxacin, activity against Clostridium spp. and Bacteroides spp. has been noted, allowing monotherapy of mixed infections.
Pharmacokinetics and routes of administration
The drugs possess pronounced pharmacokinetic advantages:
- Bioavailability: exceeds that of first-generation drugs.
- Convenience of administration: prolonged action up to 24 hours improves patient compliance.
- Routes of administration: both oral administration (per os) and parenteral administration (intravenously) are permitted.
Clinical indications
The designation "respiratory" was assigned to the group due to its ability to effectively eradicate respiratory pathogens. Main areas of application:
- Upper and lower respiratory tract infections (bronchitis, sinusitis, otitis media, pneumonia, including community-acquired).
- Gastrointestinal infections (typhoid fever, shigellosis).
- Urogenital pathology (cystitis, pyelonephritis, prostatitis, gonorrhea).
- Infectious lesions of the skin and soft tissues.
- Specific protocols: combination treatment of tuberculosis.
Side effects and safety
Adverse reactions affect several organ systems:
- Gastrointestinal tract: dyspeptic manifestations.
- Nervous system: insomnia, development of peripheral neuropathies, seizures.
- Allergy and skin: hypersensitivity reactions, as well as photosensitization caused by sunlight.
- Musculoskeletal system: arthropathies, myalgias, arthralgias, and tendon inflammation (tendinitis) associated with impaired cartilage development.
Risk factors for tendon rupture: concurrent physical exertion and glucocorticoid intake.
Contraindications: age under 18 years, pregnancy, and lactation due to the risk of cartilage damage (exception — prescription for children under life-saving indications).
Briefly: answers to topical questions
Which drugs belong to the group of respiratory fluoroquinolones?
The group of respiratory fluoroquinolones (third and fourth generations) includes levofloxacin, moxifloxacin, and gemifloxacin.
- Levofloxacin (levofloxacin) is a third-generation drug used at 0.5 g once daily.
- Moxifloxacin (moxifloxacin) is a fourth-generation drug used at 0.4 g once daily.
- Gemifloxacin (gemifloxacin) is included among respiratory fluoroquinolones.
How do respiratory fluoroquinolones interact with antacids and iron preparations?
When taken concomitantly with antacids and iron preparations, respiratory fluoroquinolones form non-absorbable complexes, which prevents their absorption and reduces bioavailability.
- Antacids contain magnesium, calcium, or aluminum ions; iron preparations also interact with fluoroquinolones.
- Correction method — fluoroquinolones must be administered strictly 4 hours after taking these medications.
"Respiratory cartilage under threat in children": respiratory is for breathing, but forbidden under 18 and during pregnancy due to chondrotoxicity.
Class and exam questions
Why are second-generation fluoroquinolones called "respiratory"?
This name stuck due to the high tropism of the drugs for respiratory tract pathogens and their ability to effectively cope with community-acquired pneumonia and bronchitis.
What are the main restrictions on prescribing this group of drugs?
The drugs are contraindicated in children under 18 years of age, pregnant, and nursing women due to the risk of cartilage damage (chondrotoxicity).
What factors increase the risk of tendon rupture during fluoroquinolone therapy?
The risk increases significantly when physical exertion during therapy is combined with the simultaneous use of glucocorticoids.
What else to study on this topic
- Comparison of activity of first- and second-generation fluoroquinolones against Gram-positive flora
- Clinical significance of the anaerobic activity of moxifloxacin in mixed infections
- Mechanisms of development of chondrotoxicity and tendon damage
- Pharmacokinetic features: bioavailability and daily concentration profile
- Safety rules regarding photosensitization and neurological side effects
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Respiratory fluoroquinolones" and 5,304 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Antibacterial Chemotherapeutic Agents"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.